Literature DB >> 416903

"Mediterranean abdominal lymphoma" or immunoproliferative small intestinal disease. Part II: pathological aspects.

V H Nassar, P A Salem, M J Shahid, S Y Alami, J B Balikian, A A Salem, S M Nasrallah.   

Abstract

The pathology of 25 cases of Mediterranean abdominal lymphoma, better designated as immunoproliferative small intestinal disease (IPSID), are reported from the American University of Beirut Hospital. The series includes nine cases with documented alpha heavy chain disease (alpha-HCD). The disease is characterized by the presence of a diffuse and compact bandlike lymphoplasmacytic infiltration of the proximal small intestinal mucosa. The presence of a concomitant malignant lymphoma in the intestine and/or mesenteric lymph nodes, and of alpha-heavy protein in the serum is commonly encountered. Two histopathologic variants of IPSID are present. The first is characterized by the diffuse infiltration of the mucosa, at sites away from tumoral masses, by either pure plasmacytic infiltration, or mixed lymphoplasmacytic infiltration. This variety is associated with the immunoblastic sarcoma type of malignant lymphoma, and with alpha chain disease (alpha-HCD). The second variant is characterized by a diffuse follicular lymphoid hyperplasia pattern in the small intestinal mucosa. The associated malignant lymphoma is diffuse and undifferentiated often having a starry-sky pattern. This variety is not associated with alpha-HCD. Both histologic variants share the same clinical antecedents. In five patients, mesenteric lymph nodes harbored immunoblastic sarcoma while the intestinal mucosae of the same patients were involved with a benign appearing lymphoplasmacytic infiltration. This finding stresses the need for staging laparatomy. Three patients, with alpha-HCD, had peripheral lymph node involvement with immunoblastic sarcoma. The disease apparently evolves in two stages: an immunoproliferative phase, probably reversible, and a later development of malignant lymphoma. The term immunoproliferative small intestinal disease accurately describes the nature of the entity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 416903     DOI: 10.1002/1097-0142(197804)41:4<1340::aid-cncr2820410419>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  The value of double-contrast study of the small intestine in immunoproliferative small intestinal disease.

Authors:  T Matsumoto; M Iida; T Matsui; H Tanaka; M Fujishima
Journal:  Gastrointest Radiol       Date:  1990

2.  The bcl-2 gene in primary B cell lymphoma of mucosa-associated lymphoid tissue (MALT).

Authors:  L Pan; T C Diss; D Cunningham; P G Isaacson
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

3.  Plasma cell infiltration of the small bowel: lack of evidence for a non-secretory form of alpha-heavy chain disease.

Authors:  N H Gilinsky; A S Mee; D W Beatty; B H Novis; G Young; S Price; L R Purves; I N Marks
Journal:  Gut       Date:  1985-09       Impact factor: 23.059

4.  Primary intestinal lymphomas.

Authors:  H F Otto; I Bettmann; J V Weltzien; J O Gebbers
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

Review 5.  The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time.

Authors:  Ruah AlYamany; Mohamed A Kharfan-Dabaja; Mehdi Hamadani; Alfadel Alshaibani; Mahmoud Aljurf
Journal:  Curr Oncol       Date:  2022-05-23       Impact factor: 3.109

6.  Mycosis fungoides associated with Mediterranean lymphoma.

Authors:  J P Cassuto; P M Kövary; J P Campagni; J Simony; R Maiolini; M Schneider
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

7.  Endoscopic features of primary small bowel lymphoma: a proposed endoscopic classification.

Authors:  M H Barakat
Journal:  Gut       Date:  1982-01       Impact factor: 23.059

8.  Middle Eastern intestinal lymphoma: a morphological and immunohistochemical study.

Authors:  P Isaacson; H S Al-Dewachi; D Y Mason
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

9.  Bone marrow involvement in a patient with alpha heavychain disease: response to tetracycline treatment.

Authors:  Zahit Bolaman; Irfan Yavasoglu; Gokhan Sargin; Gurhan Kadikoylu; Firuzan Kaçar Doğer
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-05-07       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.